Header

UZH-Logo

Maintenance Infos

Comparison of the Activity of Free and Liposomal Amphotericin B In Vitro and in a Model of Systemic and Localized Murine Candidiasis


Pahls, S; Schaffner, A (1994). Comparison of the Activity of Free and Liposomal Amphotericin B In Vitro and in a Model of Systemic and Localized Murine Candidiasis. Journal of Infectious Diseases, 169(5):1057-1061.

Abstract

Because of the toxicity of amphotericin B-desoxycholate (AmB-d) during systemic therapy, less toxic forms of AmB, which promise to have a broader therapeutic index, are under investigation. There is, however, no convincing explanation of how such preparations might be made less toxic yet retain their antifungal efficacy. In this study, the antifungal activity of a less toxic, unilamellar liposomal (1) preparation of AmB (AmBisome), which is commercially available in some countries, was compared with conventional AmB-d in vitro and in models of systemic and localized candidiasis in immunosuppressed mice. Results indicate that 1AmB has four to eight times less antifungal activity than AmB-d in all experimental settings tested. Because 1AmB is significantly less active, the therapeutic index of such preparations must be tested clinically before their use can be recommended solely on the basis of toxicity data

Abstract

Because of the toxicity of amphotericin B-desoxycholate (AmB-d) during systemic therapy, less toxic forms of AmB, which promise to have a broader therapeutic index, are under investigation. There is, however, no convincing explanation of how such preparations might be made less toxic yet retain their antifungal efficacy. In this study, the antifungal activity of a less toxic, unilamellar liposomal (1) preparation of AmB (AmBisome), which is commercially available in some countries, was compared with conventional AmB-d in vitro and in models of systemic and localized candidiasis in immunosuppressed mice. Results indicate that 1AmB has four to eight times less antifungal activity than AmB-d in all experimental settings tested. Because 1AmB is significantly less active, the therapeutic index of such preparations must be tested clinically before their use can be recommended solely on the basis of toxicity data

Statistics

Citations

Dimensions.ai Metrics
41 citations in Web of Science®
47 citations in Scopus®
Google Scholar™

Altmetrics

Downloads

13 downloads since deposited on 12 Oct 2018
8 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:National licences > 142-005
Dewey Decimal Classification:570 Life sciences; biology
610 Medicine & health
Scopus Subject Areas:Health Sciences > Immunology and Allergy
Health Sciences > Infectious Diseases
Language:English
Date:1 May 1994
Deposited On:12 Oct 2018 08:27
Last Modified:31 Jul 2020 02:06
Publisher:Oxford University Press
ISSN:0022-1899
OA Status:Green
Free access at:Publisher DOI. An embargo period may apply.
Publisher DOI:https://doi.org/10.1093/infdis/169.5.1057
Related URLs:https://www.swissbib.ch/Search/Results?lookfor=nationallicenceoxford101093infdis16951057 (Library Catalogue)

Download

Green Open Access

Download PDF  'Comparison of the Activity of Free and Liposomal Amphotericin B In Vitro and in a Model of Systemic and Localized Murine Candidiasis'.
Preview
Content: Published Version
Language: English
Filetype: PDF (Nationallizenz 142-005)
Size: 456kB
View at publisher